ClearPoint director gets 442-share stock award

Richards Timothy T. reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Richards Timothy T. reported acquisition or exercise transactions in this Form 4 filing.

ClearPoint Neuro director Timothy T. Richards received 442 shares of Common Stock as compensation, valued at $9.10 per share. The award was issued under the company’s Sixth Amended and Restated 2013 Incentive Compensation Plan in payment of fees owed under the Non-Employee Director Compensation Plan.

Following this grant, Richards directly holds 80,196 shares of ClearPoint Neuro common stock. The shares were issued at the closing price of the company’s common stock on March 31, 2026, making this a routine, stock-settled director fee payment rather than an open-market purchase.

Insider Trade Summary

Grant/Award: 442 shares

Grant/Award 1 txn

Insider Richards Timothy T.

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	442	$9.10	$4K

Holdings After Transaction: Common Stock — 80,196 shares (Direct)

Footnotes (1)

1. F1. These shares were issued pursuant to the issuer's Sixth Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at the closing price of the issuer's common stock at March 31, 2026.

Key Figures

Shares granted: 442 shares Grant valuation price: $9.10 per share Shares owned after grant: 80,196 shares

3 metrics

Shares granted 442 shares Stock-based director fee on 2026-04-01

Grant valuation price $9.10 per share Closing price on March 31, 2026 used for award

Shares owned after grant 80,196 shares Director’s direct CLPT holdings following transaction

Key Terms

Sixth Amended and Restated 2013 Incentive Compensation Plan, Non-Employee Director Compensation Plan, Common Stock, Grant, award, or other acquisition

4 terms

Sixth Amended and Restated 2013 Incentive Compensation Plan financial

"These shares were issued pursuant to the issuer's Sixth Amended and Restated 2013 Incentive Compensation Plan"

Non-Employee Director Compensation Plan financial

"in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan"

Common Stock financial

"These shares were issued pursuant to the issuer's Sixth Amended and Restated 2013 Incentive Compensation Plan"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did ClearPoint Neuro (CLPT) report for Timothy T. Richards?

ClearPoint Neuro reported that director Timothy T. Richards received 442 shares of Common Stock as a stock-based fee. The shares were granted under company compensation plans, reflecting routine director compensation rather than an open-market trade or discretionary share purchase.

At what price were Timothy T. Richards’ CLPT shares granted?

The 442 shares granted to Timothy T. Richards were issued at $9.10 per share, equal to ClearPoint Neuro’s closing stock price on March 31, 2026. This price was used solely to value the stock-based director fee under the company’s approved incentive plan.

How many ClearPoint Neuro (CLPT) shares does Timothy T. Richards own after this grant?

After the 442-share grant, Timothy T. Richards directly owns 80,196 shares of ClearPoint Neuro Common Stock. This updated holding reflects his position following the routine director fee payment made in stock under the company’s incentive compensation and non-employee director plans.

Was Timothy T. Richards’ CLPT transaction an open-market buy or a compensation award?

The transaction was a compensation award, not an open-market buy. The 442 shares were issued under ClearPoint Neuro’s Sixth Amended and Restated 2013 Incentive Compensation Plan as payment of fees owed under the Non-Employee Director Compensation Plan, using the March 31, 2026 closing price.

Which ClearPoint Neuro plans governed Timothy T. Richards’ 442-share CLPT grant?

The grant was made under ClearPoint Neuro’s Sixth Amended and Restated 2013 Incentive Compensation Plan. It satisfied fees owed to Timothy T. Richards under the company’s Non-Employee Director Compensation Plan, as amended and restated, aligning director pay with shareholder interests through equity compensation.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/02/2026 - 02:49 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Richards Timothy T.

(Last) (First) (Middle)

C/O CLEARPOINT NEURO, INC.

120 S. SIERRA AVE., SUITE 100

(Street)

SOLANA BEACH CALIFORNIA 92075

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ClearPoint Neuro, Inc. [ CLPT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/01/2026		A		442	A	$9.1(1)	80,196	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These shares were issued pursuant to the issuer's Sixth Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at the closing price of the issuer's common stock at March 31, 2026.

	/s/ Danilo D'Alessandro, by Power of Attorney for Timothy T. Richards	04/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)